Screener
Recursion Pharmaceuticals, Inc. RXRX Accrued license fees
Accrued license fees at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept rxrx:AccruedLicenseFeeCurrent.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| (in thousands) | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accrued early discovery expenses | 4,621 | 4,581 |
| Accrued professional fees | 1,167 | 1,232 |
| Materials received not invoiced | 171 | 703 |
| Accrued taxes, other than income taxes | 3,557 | 3,912 |
| Unearned grants | 1,909 | — |
| Accrued license fees | 3,000 | 3,000 |
| Accrued other expenses | 13,458 | 14,060 |
| Accrued expense and other liabilities | $56,936 | $70,230 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s accrued license fees?
- Recursion Pharmaceuticals, Inc. (RXRX) reported accrued license fees of $3M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s accrued license fees changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s accrued license fees decreased by 0.0% year-over-year, from $3M to $3M.
- What does accrued license fees mean?
- Accrued license fees as reported by Recursion Pharmaceuticals, Inc. Class A Common Stock.
Ask your AI about Recursion Pharmaceuticals, Inc.'s accrued license fees.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude